XBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-09-21), the Trailing Annual Dividend Yield of Xenetic Biosciences is 0.00%.
The historical rank and industry rank for Xenetic Biosciences's Dividend Yield % or its related term are showing as below:
Xenetic Biosciences's Dividend Payout Ratio for the three months ended in Jun. 2024 was 0.00.
As of today (2024-09-21), the Forward Dividend Yield % of Xenetic Biosciences is 0.00%.
Xenetic Biosciences's Dividends per Share for the three months ended in Jun. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Xenetic Biosciences's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Xenetic Biosciences Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Xenetic Biosciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Xenetic Biosciences (NAS:XBIO) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Xenetic Biosciences's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Grigory G. Borisenko | director | 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701 |
Alexey Andreevich Vinogradov | director | C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701 |
Adam Logal | director | OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137 |
James Eric Callaway | director | 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421 |
Dmitry Genkin | director | 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421 |
James F Parslow | officer: Chief Financial Officer | C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421 |
Curtis Lockshin | officer: Chief Scientific Officer | 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137 |
Benz Edward J. Jr | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Roger D. Kornberg | director | 345 WALSH ROAD, ATHERTON CA 94027 |
Darlene M Deptula-hicks | director | C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062 |
Jeffrey F Eisenberg | director | 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421 |
Firdaus J. Dastoor | director | 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421 |
Michael Scott Maguire | director | 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421 |
Roman Knyazev | director | 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421 |
Pharmsynthez Pjsc | 10 percent owner | 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 05-03-2023
By PRNewswire PRNewswire • 07-30-2021
By ACCESSWIRE ACCESSWIRE • 06-02-2022
By ACCESSWIRE ACCESSWIRE • 09-08-2021
By ACCESSWIRE ACCESSWIRE • 09-09-2021
By ACCESSWIRE ACCESSWIRE • 04-27-2022
By ACCESSWIRE • 07-05-2023
By ACCESSWIRE ACCESSWIRE • 03-23-2022
By ACCESSWIRE ACCESSWIRE • 05-04-2023
By ACCESSWIRE ACCESSWIRE • 06-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.